(R)-3-(6’-hydroxy-2’,4’,6’-trimethyl-7’-oxo-6’,7’-dihydrospiro[cyclopropane-1,5’-inden]-3’-yl)propanoic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (R)-3-(6’-hydroxy-2’,4’,6’-trimethyl-7’-oxo-6’,7’-dihydrospiro[cyclopropane-1,5’-inden]-3’-yl)propanoic acid
• 英文别名: (R)-3-(6'-hydroxy-2',4',6'-trimethyl-7'-oxo-6',7'-dihydrospiro[cyclopropane-1,5'-inden]-3'-yl)propanoic acid；3-[(5'R)-5'-hydroxy-2',5',7'-trimethyl-4'-oxospiro[cyclopropane-1,6'-indene]-1'-yl]propanoic acid
• 化学式: C₁₇H₂₀O₄
• 分子量: 288.343
• InChiKey: OIHUEGVRKLJECX-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  雌酚酮 、 (R)-3-(6’-hydroxy-2’,4’,6’-trimethyl-7’-oxo-6’,7’-dihydrospiro[cyclopropane-1,5’-inden]-3’-yl)propanoic acid 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以40 mg的产率得到(13S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 3-((R)-6'-hydroxy-2',4',6'-trimethyl-7'-oxo-6',7'-dihydrospiro [cyclopropane-1,5'-inden]-3'-yl)propanoate
  参考文献：
  名称：

  AFFINITY ILLUDOFULVENE CONJUGATES

  摘要：

  在该发明实施例中，用于治疗细胞群的组合物包括一种药物。该药物部分可以是伊卢多富烯类似物。在该发明实施例中，用于治疗细胞群的组合物包括亲和药物结合物（AMC）。亲和部分可以是抗体、抗体片段、受体蛋白、肽生长因子、抗血管生成蛋白、特异结合肽、蛋白酶可切割肽、糖肽、肽、肽毒素、蛋白毒素和寡核苷酸。亲和部分可以通过连接剂与药物共价结合。

  公开号：

  US20210155583A1
• 作为产物：
  描述：

  (R)-3-(6’-hydroxy-2’,4’,6’-trimethyl-7’-oxo-6’,7’-dihydrospiro[cyclopropane-1,5’-inden]-3’-yl)propanal 在 jones reagent 作用下， 以 丙酮 为溶剂， 反应 0.33h， 以62%的产率得到(R)-3-(6’-hydroxy-2’,4’,6’-trimethyl-7’-oxo-6’,7’-dihydrospiro[cyclopropane-1,5’-inden]-3’-yl)propanoic acid
  参考文献：
  名称：

  Structure−Activity Studies of Antitumor Agent Irofulven (Hydroxymethylacylfulvene) and Analogues

  摘要：

  Many analogues of the antitumor agent irofulven have been readily prepared by replacing the allylic hydroxyl with a variety of nucleophiles. Analogues of acylfulvene (the precursor to irofulven) were also prepared by Michael reaction with acrolein. The toxicity of the analogues was determined, as well as preclinical antitumor activity. Several analogues exhibited good activity in mouse xenografts. Structural requirements for activity are discussed.

  DOI：

  10.1021/jo010458z

文献信息

• ILLUDIN ANALOGS USEFUL AS ANTITUMOR AGENTS
  申请人：McMorris Trevor C.

  公开号：US20080306013A1

  公开（公告）日：2008-12-11

  The present invention provides illudin analogs of the general formula (I): where R 1 is (CH 2 ) n —X—Y or H; n is 0 to 4; X is O or S or N or absent; and Y is an optionally substituted (C 1 -C 8 )alkyl, (C 6 -C 10 )aryl, (C 6 -C 10 )aryl(C 1 -C 4 )alkyl or cyclo(C 3 -C 6 )alkyl optionally comprising one or more heteroatoms; a monosaccharide, an amino acid residue, or H when n is 2-4; R 2 is absent; or R 1 and R 2 together comprise a 5-7 membered cyclic ring; R 3 is (C 1 -C 4 )alkyl or H; R 4 is H, SCH 2 CO 2 (C 1 -C 4 )alkyl, O—(C 5 -C 12 )aryl or —S—(C 5 -C 12 )aryl; R 5 is H, OH or absent; R 6 is (C 1 -C 4 )alkyl or absent; R 7 is OH or OSi((C 1 -C 4 )alkyl) 3 ; or R 6 and R 7 together are ethylenedioxy; R 8 is optionally substituted (C 1 -C 4 )alkyl; and the bonds represented by --- are individually present or absent. The invention further provides dimers comprising analogs of formula (I).

  本发明提供了通式（I）的伊卢丁类似物，其中R1是（CH2）n-X-Y或H；n为0到4；X是O或S或N或缺失；Y是一个可选取代的（C1-C8）烷基，（C6-C10）芳基，（C6-C10）芳基（C1-C4）烷基或环（C3-C6）烷基，可包含一个或多个杂原子；单糖，氨基酸残基或H，当n为2-4时；R2不存在；或R1和R2共同组成5-7成员环；R3是（C1-C4）烷基或H；R4是H，SCH2CO2（C1-C4）烷基，O-（C5-C12）芳基或-S-（C5-C12）芳基；R5是H，OH或不存在；R6是（C1-C4）烷基或不存在；R7是OH或OSi（（C1-C4）烷基）3；或R6和R7共同是乙二酸二甲酯基；R8是可选取代的（C1-C4）烷基；由---表示的键分别存在或不存在。本发明还提供了包含通式（I）类似物的二聚体。
• METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES
  申请人：Kelner, Michael

  公开号：EP3667323A1

  公开（公告）日：2020-06-17

  The present invention relates to compositions, methods and devices for treating cancer with illudofulvenes including methods to detect the expression levels of genes encoding biomarkers in cancer patients and to predict the responsiveness of cancer patients to illudofulvenes.

  本发明涉及用紫杉醇治疗癌症的组合物、方法和装置，包括检测癌症患者体内编码生物标志物的基因表达水平和预测癌症患者对紫杉醇反应性的方法。
• Affinity medicant conjugate
  申请人：AF Chemicals, LLC

  公开号：US10285955B2

  公开（公告）日：2019-05-14

  In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.

  在本发明的一个实施方案中，一种用于治疗细胞群的组合物包含一种亲和药剂共轭物（AMC）。药剂分子可以是包括酰化芬在内的毒素或药物分子。亲和剂可以是抗体、结合蛋白、类固醇、脂质、生长因子、蛋白质、肽或非肽。亲和分子可以通过连接体与药物共价结合。新型连接体可根据溶液 pH 值定向连接半胱氨酸、精氨酸或赖氨酸残基，从而更灵活地保留和/或生成 AMC 中的特定表位。
• Affinity medicant conjugates
  申请人：AF Chemicals, LLC

  公开号：US11135182B2

  公开（公告）日：2021-10-05

  In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.

  在本发明的一个实施方案中，一种用于治疗细胞群的组合物包含一种亲和药剂共轭物（AMC）。药剂分子可以是包括酰化芬在内的毒素或药物分子。亲和剂可以是抗体、结合蛋白、类固醇、脂质、生长因子、蛋白质、肽或非肽。亲和分子可以通过连接体与药物共价结合。新型连接体可根据溶液 pH 值定向连接半胱氨酸、精氨酸或赖氨酸残基，从而更灵活地保留和/或生成 AMC 中的特定表位。
• Methods, compositions and devices for treating cancer with illudofulvenes
  申请人：AF Chemicals, LLC

  公开号：US11160807B1

  公开（公告）日：2021-11-02

  In an embodiment of the invention, a method of treating cancer includes screening to select a patient population that will respond to an Illudofulvene Analog composition based on the presence of one or more Transcription Coupled Repair (TCR) mutations, deletions or other events interfering with TCR biomarker expression in combination with upregulation of Myc and/or PTGR biomarker expression and treating the patient population with the Illudofulvene Analog composition.

  在本发明的一个实施方案中，治疗癌症的方法包括根据存在一种或多种转录偶联修复（TCR）突变、缺失或其他干扰TCR生物标志物表达的事件，结合Myc和/或PTGR生物标志物表达的上调，筛选出对Illudofulvene类似物组合物有反应的患者群体，并用Illudofulvene类似物组合物治疗该患者群体。